Want to join the conversation?
$LLY 2Q15 PR: Revenue was $4978.7MM. GAAP net income was $600.8MM or $0.56 per diluted share. Revenue grew 1% with inclusion of Novartis Animal Health & higher volume for several products, including Cyramza and Trulicity; these factors were largely offset by unfavorable effect of FX rates & residual impact of Cymbalta and Evista patent expirations.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.